To evaluate the safety and efficacy of insulin pump therapy in Iranian people with type 1 diabetes on an insulin regimen with multiple daily injections.
This study was an observational, non-interventional, prospective, multicentre survey with 6 month-follow-up time in subjects with type 1 diabetes on multiple daily insulin injections (MDI) for whom a continuous subcutaneous insulin infusion (CSII) therapy was recommended. Accu-Chek Combo system insulin pumps were used.
A total of 20 patients were included. The mean age was 12.6 ± 0.61 years. The mean duration of diabetes was 5.7 ± 0.54 years. The mean HbA1c was 9.72±0.5% at baseline, whereas this figure was reported to be 7.58±0.28% by the end of the study. A mean absolute change of -2.14% was observed from baseline. The proportion of patients reaching the target of HbA1c<7% was 30% at month 6. The rate of major and nocturnal hypoglycemia was 41.7 (CI: 5.9 – 77.4) per 1,000 person-months.
Insulin pump therapy effectively reduced HbA1c in Iranian patients with type 1 diabetes with acceptable safety profile.